SIX Swiss Exchange · Financial Services
Invest in EvoNext stock from India
Indian and foreign residents can buy EvoNext (EVE) shares directly through Paasa.
By Paasa · Updated
EvoNext at a glance
- Price
- CHF 2.08-CHF 0.14 (6.31%)
- Market cap
- CHF 15.00M
- Day range
- CHF 2.06 – CHF 2.21
- P/E
- -23.01
- Dividend yield
- None
- Volume
- 28.78K
- 1 month
- -13.33%
- 6 months
- +128.57%
- YTD
- +156.79%
- 1 year
- +108.00%
- 5 years
- -94.29%
EvoNext statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CHF 0.0 | CHF 0.0 | CHF 9.4M | CHF 15.5M | CHF 9.9M |
| Gross profit | CHF 0.0 | CHF 0.0 | −CHF 4.8M | −CHF 8.9M | −CHF 9.3M |
| Operating income | −CHF 678.4K | CHF 788.7K | −CHF 24.0M | −CHF 40.4M | −CHF 42.0M |
| Net income | −CHF 652.7K | CHF 1.0M | −CHF 105.2M | −CHF 43.4M | −CHF 41.3M |
| Earnings per share | −CHF 0.09 | CHF 0.14 | −CHF 19.50 | −CHF 10.13 | −CHF 11.72 |
| EBITDA | −CHF 652.1K | CHF 3.7M | −CHF 98.4M | −CHF 34.5M | −CHF 31.8M |
| Total assets | CHF 6.8M | CHF 7.5M | CHF 9.8M | CHF 131.0M | CHF 156.2M |
| Total debt | CHF 0.0 | CHF 0.0 | CHF 0.0 | CHF 15.1M | CHF 10.8M |
| Cash and short-term investments | CHF 5.6M | CHF 6.8M | CHF 5.8M | CHF 5.1M | CHF 11.0M |
| Shareholders' equity | CHF 5.9M | CHF 6.6M | CHF 5.6M | CHF 106.2M | CHF 131.8M |
| Operating cash flow | −CHF 1.1M | −CHF 2.4M | −CHF 9.3M | −CHF 18.9M | −CHF 29.8M |
| Free cash flow | CHF 0.0 | −CHF 2.4M | −CHF 9.7M | −CHF 21.1M | −CHF 33.6M |
| Capital expenditure | CHF 1.1M | CHF 0.0 | −CHF 466.6K | −CHF 2.3M | −CHF 3.8M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CHF; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Basilea Pharmaceutica | BSLN.SW | CHF 69.90 | CHF 865.13M |
| Santhera Pharmaceuticals | SANN.SW | CHF 15.50 | CHF 229.89M |
| Newron Pharmaceuticals | NWRN.SW | CHF 8.05 | CHF 167.49M |
| Molecular Partners | MOLN.SW | CHF 3.32 | CHF 124.54M |
| Addex Therapeutics | ADXN.SW | CHF 0.02 | CHF 3.13M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in EvoNext from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to CHF when you buy.
Step 3
Search EVE and buy
Find EvoNext by name or by its ticker, EVE, and place your order.
Why invest in EvoNext from India
What EvoNext does
EvoNext Holdings SA is dedicated to the exploration, creation, and distribution of pioneering ingredients across the nutritional, health, and wellness domains. Founded in 2004, the company's inception is attributed to Alexandra Santana Sørensen, Søren V. EvoNext operates in the Shell Companies industry within the Financial Services sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy EvoNext stock from India?
Yes. Indian residents and NRIs can buy EvoNext (EVE) shares directly through Paasa. EvoNext is listed on the SIX Swiss Exchange, in the Shell Companies industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell EvoNext shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the CHF/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.